Connexin Antibodies

Zymed Laboratories has developed monoclonal and polyclonal antibodies to the three most commonly studied connexins: 26, 32, and 43. All these antibodies are excellent for Western blotting and tissue staining-- please call about other applications and species reactivity. A sampler pack containing separate aliquots of each antibody also available. These antibodies are available only from Zymed Laboratories.

Ordering Information:

<table>
<thead>
<tr>
<th>Cat. no.</th>
<th>Description</th>
<th>Western Blot</th>
<th>Immunoprecipitation</th>
<th>Immunohistochemistry</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>71-0500</td>
<td>Rabbit Anti-Connexin-26</td>
<td>yes</td>
<td>NT</td>
<td>yes</td>
<td>50 µg / 100 µl</td>
</tr>
<tr>
<td>71-0600</td>
<td>Rabbit Anti-Connexin-32</td>
<td>yes</td>
<td>NT</td>
<td>yes</td>
<td>50 µg / 100 µl</td>
</tr>
<tr>
<td>71-0700</td>
<td>Rabbit Anti-Connexin-43</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>50 µg / 100 µl</td>
</tr>
<tr>
<td>13-8100</td>
<td>Mouse Anti-Connexin-26</td>
<td>yes</td>
<td>NT</td>
<td>yes</td>
<td>100 µg / 100 µl</td>
</tr>
<tr>
<td>13-8200</td>
<td>Mouse Anti-Connexin-32</td>
<td>yes</td>
<td>NT</td>
<td>NT</td>
<td>100 µg / 100 µl</td>
</tr>
<tr>
<td>13-8300</td>
<td>Mouse Anti-Connexin-43</td>
<td>yes</td>
<td>NT</td>
<td>yes</td>
<td>100 µg / 100 µl</td>
</tr>
<tr>
<td>90-0500</td>
<td>Sampler Pack</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Contains 10 µg of Rabbit / 20 µg of Mouse)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NT - Not Tested

Other Products:

- HistoMouse™ SP Kit (for detecting mouse primary antibodies)
- Protein A-Sepharose
- Streptavidin-HRP
- Rabbit anti-Phosphotyrosine-HRP
- Goat Anti-Mouse-HRP (excellent for chemiluminescence)

Next day service!
CANCER AND THE CELL CYCLE

Joint Conference of the
American Association for Cancer Research
and the
Swiss Institute for Experimental Cancer Research

January 17-20, 1996
Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne, Switzerland

CONFERENCE CHAIRPERSONS

Edward E. Harlow / Charlestown, MA
Viesturs Simanis / Lausanne, Switzerland

SCIENTIFIC PROGRAM

Introduction
Tim Hunt / London, England
J. Michael Bishop / San Francisco, CA

Control of CDKS
David Beach / Cold Spring Harbor, NY
Charles J. Sherr / Memphis, TN
Stephen J. Elledge / Houston, TX
James M. Roberts / Seattle, WA
Christian Lehner / Tübingen, Germany

Coordination of S Phase and M Phase
Matthias Peter / San Francisco, CA
Paul Nurse / London, England
Kim Nasmyth / Vienna, Austria
John Diffley / Herts, England

p53
Arnold J. Levine / Princeton, NJ
David P. Lane / Dundee, Scotland
Michael B. Kastan / Baltimore, MD
Eileen White / Piscataway, NJ
Richard Iigo / Epalinges, Switzerland

The Role of myc in Life and Death
Robert Eisenman / Seattle, WA
Gerard I. Evan / London, England
Martin Ellers / Heidelberg, Germany
Bruno Amati / Epalinges, Switzerland

GI Progression in Higher Eukaryotes
Edward E. Harlow / Charlestown, MA
David M. Livingston / Boston, MA
Robert A. Weinberg / Cambridge, MA
Rene Bernards / Amsterdam, The Netherlands

Checkpoints
Andrew Murray / San Francisco, CA
Anthony Carr / Brighton, England
Ted A. Weinert / Tucson, AZ
Viesturs Simanis / Epalinges, Switzerland
Erich A. Nigg / Epalinges, Switzerland

Meeting Summary
Benjamin Lewin / Cambridge, MA

Additional Speakers to be Announced

Applicants are encouraged to submit abstracts for poster presentation.

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
Ann Wayne
Hematology/Oncology
PHARMACOLOGIST

Pharmacology.

They will:

* Review basic knowledge applicable to chemoprevention
* Present available results of trials
* Discuss on-going studies in the practical application of potential chemopreventive agents for cancer control
* Evaluate the potentialities of these new tools, and indicate future developments for research in the area

Invited speakers include:

<table>
<thead>
<tr>
<th>John Bailar III, Montreal</th>
<th>Brian Henderson, Los Angeles</th>
<th>Hélène Sancho-Garnier, Montpellier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jack Cuzick, London</td>
<td>Paul Kleihues, IARC</td>
<td>Carl G. Schmidt, Essen</td>
</tr>
<tr>
<td>John Evans, Edinburgh</td>
<td>Robert Kroes, Bilthoven</td>
<td>Umberto Veronesi, Milan</td>
</tr>
<tr>
<td>Curt Harris, Bethesda</td>
<td>Martin Lipkin, New York</td>
<td>Bernard Weinstein, New York</td>
</tr>
</tbody>
</table>

The forum will be followed by a 3-day teaching seminar

For further information and registration form, please write to:

Dr Morando Soffritti or Dr Fiorella Belpoggi
Cancer Research Centre
Castello di Bentivoglio
40010 Bentivoglio, Bologna, Italy

Send CV to: Dr. Anthony Shields, Division of Hematology/Oncology, Wayne State University, c/o Harper Hospital, 3990 John R, 5 Hudson, Detroit, MI 48201. Telephone: (313) 745-6258 FAX: (313) 993-0559

MCV/VCU seeks a nationally recognized leader of cancer research activity as Director of its Massey Cancer Center, an NCI designated Center since its inception in 1974 with programs in basic and clinical research. Applicant must hold an M.D. or Ph.D. degree, qualify for appointment at the rank of Professor, and demonstrate significant cancer-related scholarly accomplishments. Substantive managerial skills are strongly desired.

Experience working in an academic medical center and culturally diverse environment is preferred. Interested applicants should submit CV by January 1, 1996 to:

Anthony V. Proto, M.D., Chair, Search Committee for the Director, Massey Cancer Center
MCV/VCU, P. O. Box 980470
Richmond, Virginia 23298-0470

The University is an Equal Opportunity/Affirmative Action Employer.

Women, minorities, persons with disabilities are encouraged to apply.
AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Cancer Susceptibility Genes and Molecular Carcinogenesis

February 19-25, 1996
The Keystone Resort, Keystone, Colorado

CONFERENCE CHAIRPERSONS
Allan Balmain / Glasgow, Scotland
Curtis C. Harris / Bethesda, MD
Kenneth Olden / Research Triangle Park, NC

SCIENTIFIC PROGRAM

Keynote Address
Harold E. Varmus / Bethesda, MD

Genetic Susceptibility of Animal Models - Inbred Strains
William F. Dove / Madison, WI
Norman R. Drinkwater / Madison, WI
Cheryl Lyn Walker / Smithville, TX
Peter Demant / Amsterdam, The Netherlands

Genetic Susceptibility of Animal Models - Transgenic and Knockout
Douglas Hanahan / San Francisco, CA
Tyler E. Jacks / Cambridge, MA
Michael P. Rosenberg / Research Triangle Park, NC

Genetic Susceptibility of Humans - Xenobiotic Metabolism
Frank J. Gonzalez / Bethesda, MD
Fred F. Kadiuabar / Jefferson, AR
Peter G. Shields / Bethesda, MD
C. Roland Wolf / Dundee, Scotland

Genetic Susceptibility of Humans - DNA Repair
Isabel Mellon / Lexington, KY
Jan H. Hoeljmakers / Rotterdam, The Netherlands
Richard D. Kolodner / Boston, MA

Genetic Susceptibility of Humans - Tumor Suppressor Genes
David P. Lane / Dundee, Scotland
Louise C. Strong / Houston, TX
Curtis C. Harris / Bethesda, MD
Richard D. Klausner / Bethesda, MD

Senescence and Terminal Differentiation
J. Carl Barrett / Research Triangle Park, NC
Jerry W. Shay / Dallas, TX
Jennifer A. Pietenpol / Nashville, TN
Harold L. Moses / Nashville, TN

Apoptosis
Tona M. Gilmer / Research Triangle Park, NC
Judith Campisi / Berkeley, CA
Michael B. Kastan / Baltimore, MD
Eileen White / Piscataway, NJ
Scott W. Lowe / Cambridge, MA

Molecular Carcinogenesis in Animal Models and Humans - Skin
Allan Balmain / Glasgow, Scotland
Douglas E. Brash / New Haven, CT

Molecular Carcinogenesis in Animal Models and Humans - Liver and Breast
Kenneth Olden / Research Triangle Park, NC
Henry C. Pitot / Madison, WI
Xin W. Wang / Bethesda, MD
Roger W. Wiseman / Research Triangle Park, NC
Mary-Claire King / Seattle, WA

Molecular Carcinogenesis in Animal Models and Humans - Brain
Terry A. Van Dyke / Chapel Hill, NC
Paul Kleihues / Lyon, France

Applicants are encouraged to submit abstracts for poster presentation.

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
The Camptothecins: From Discovery to the Patient

A New York Academy of Sciences Conference
February 7–10, 1996 - Bethesda, Maryland

The Camptothecins have demonstrated significant activity in early clinical trials for cancer. This meeting will include presentations on mechanistic studies, new derivatives, pharmacology, medicinal chemistry, and clinical results. Covering all aspects of these drugs from basic science to clinical use, this conference will be of interest to a wide range of scientists and clinicians, not only those who are working with this very promising class of anti-cancer agents, but also other individuals who are interested in bridging basic research and clinical application of new therapies.

Organizers
B.C. Giovannella, P. Pantazis, M.L. Rothenberg

Invited Speakers

For registration information, contact:
Conference Department, New York Academy of Sciences
2 East 63rd Street, New York, NY 10021
Phone 212-838-0230, ext. #324 or Fax 212-838-5640
E-mail: conference@nyas.org

LEUKEMIA RESEARCH FOUNDATION GRANTS

The Leukemia Research Foundation, Inc. announces that funds are available to support research in the field of leukemia. The goal of the grant program is to support new investigators; preference will be given to applicants proposing new lines of investigation. Currently, two types of Grants are being funded: research grants and postdoctoral fellowships. Grants and fellowships are for a one-year period and may be renewable for a second year. DEADLINE FOR RECEIPT OF COMPLETED GRANT APPLICATIONS IS FEBRUARY 15, 1996.

RESEARCH GRANT POLICIES:

1. Eligibility is restricted to investigators who are staff members of a university, hospital, or a non-profit research institute. The applicant must be less than five years beyond the end of training at the time of the proposed starting date of the grant award.
2. Maximum budget request is $35,000. The funds may not be used for salary support of the principal investigator.

POSTDOCTORAL FELLOWSHIP POLICIES:

1. Maximum budget request is $20,000. The funds usually are used to support the fellow's salary.
2. Eligibility is restricted to postdoctoral trainees with a M.D. or Ph.D. degree. The fellow must have no greater than three years of postdoctoral training (excluding medical residency) at the time of the proposed starting date of the grant award.

For further information and applications, contact:
Hollis R. Brownstein, Chairman
Medical Advisory Committee
Leukemia Research Foundation, Inc.
4761 West Touhy Avenue, Suite 211
Lincolnwood, IL 60646
Phone: 1-708-982-1480
Fax: 1-708-581-0779

THE SURGERY BRANCH, NATIONAL CANCER INSTITUTE, NIH, IS SEEKING PATIENTS FOR ONGOING CLINICAL TREATMENT PROGRAMS.

PATIENTS WITH THE FOLLOWING MALIGNANCIES ARE BEING TREATED UNDER COMBINED MODALITY OR INNOVATIVE IMMUNOTHERAPY PROGRAMS:

- METASTATIC MELANOMA AND KIDNEY CANCER
- STAGE II OR LOCALLY ADVANCED BREAST CANCER
- METASTATIC COLORECTAL CANCER TO THE LIVER
- LOCOREGIONAL GASTRIC OR PANCREATIC CANCER
- MESOTHELIOMA, PULMONARY METASTASES, STAGE IIIA, B LUNG CANCER OR ESOPHAGEAL CANCER
- LOCALIZED SOFT TISSUE SARCOMAS
- PERITONEAL CARCINOMATOSIS

CARE FOR ALL PATIENTS IS PROVIDED AT THE CLINICAL CENTER, NIH, BETHESDA, MARYLAND.

FOR MORE INFORMATION ON CANCER PROGRAMS, PLEASE CALL (301) 496-1533

A PUBLIC SERVICE ANNOUNCEMENT COURTESY OF THIS PUBLICATION
Winners of the highly coveted General Motors Cancer Research Foundation awards were announced recently by Foundation President Joseph G. Fortner. This year’s awards went to scientists from the United States and Germany who made groundbreaking discoveries in molecular biology, epidemiology, and clinical research. The Charles F. Kettering Award for outstanding contributions to cancer treatment was made to Norbert Brock (top left), former chief of the Department of Cancer Research of ASTA Werke AG in Bielefeld, Germany; the Charles S. Mott Award for outstanding progress in research on cancer causation and prevention was shared by Frederick P. Li (top right) of the Dana-Farber Cancer Institute, Boston, MA, and Joseph F. Fraumeni, Jr. (bottom left), of the National Cancer Institute, Bethesda, MD; and the Alfred P. Sloan, Jr., Medal for outstanding basic science contributions was awarded to Edward E. Harlow, Jr. (bottom right), of Massachusetts General Hospital Cancer Center, Charlestown, MA. Each prize includes a $100,000 award and a commemorative gold medal.

Dr. Brock was honored for introducing to cancer treatment a series of compounds, cyclophosphamide, ifosfamide, and trofosfamide, that are still among the most successful and commonly used anticancer agents. He began by using the “transport form/active form” principle, in which a highly reactive drug is applied in a chemically masked inactive transport form and then converted into the active form in the body, preferably in the tumor cell. This principle was then extended to highly reactive nitrogen mustards, and resulted in the compounds described above. In 1978, he developed a regional, and thus organ-specific, detoxification of the urototoxic oxazaphosphorine cytostatics by “Mesna.”

Dr. Brock graduated from the University of Düsseldorf in 1935, and pursued further professional training at the University’s Institute of Pathology and in the Medical Unit of the University Hospital before continuing his training in the Institute of Pharmacology of the Friedrich Wilhelm University in Berlin under the leadership of Wolfgang Heubner and Hermann Druckrey. He was then a lecturer at Berlin University and the University of Münster before he became Head of the Department of Pharmacology, Toxicology, and Experimental Cancer Research of ASTA Werke AG. An AACR member since 1974, Dr. Brock received the Bruce F. Cain Memorial Award from the Association in 1988.

Drs. Li and Fraumeni were honored for their discovery of an inherited multiple-cancer syndrome that now bears their names (Li-Fraumeni syndrome). Their use of a combined clinical, analytical, and experimental approach led to the development of a genetic test for the syndrome and to recommendations for predictive genetic testing in cancer-prone families. Their work has also served as a paradigm for the evolving field of molecular and genetic epidemiology.

Dr. Li graduated from New York University and the University of Rochester School of Medicine, where he also completed his internship in internal medicine. After a residency at Bellevue Hospital in New York, he joined the Epidemiology Branch at the National Cancer Institute. He completed fellowships in hematology and medical oncology and received his master’s degree in demography from Georgetown University. He was Head of the National Cancer Institute Epidemiology Branch Field Station in Boston for two decades. Currently, he is Professor of Clinical Cancer Epidemiology at Harvard School of Public Health and Professor of Medicine at Harvard Medical School. Dr. Li has been an AACR member since 1975 and recently began a term on the Association’s Board of Directors (1995–1998). His other service to the AACR includes chairing the Epidemiology Section of the Program Committee in 1989 and the Rosenthal Subcommittee of the Awards Committee in 1991, and serving on the Publications Committee from 1991 to 1993 and the Epidemiology and Prevention Subcommittee of the Program Committee from 1992 to 1993. Dr. Li also served as an Associate Editor for Cancer Research from 1990 to 1995, and is currently an Associate Editor for Cancer Epidemiology, Biomarkers & Prevention. He received the Richard and Hinda Rosenthal Foundation Award from the AACR in 1988 and the American Cancer Society Award for Research Excellence in Epidemiology and Prevention in 1995.

Dr. Fraumeni graduated from Harvard College and New University Medical School, then completed a residency in medicine at Johns Hopkins Hospital and Memorial Sloan-Kettering Cancer Center. He also received his master’s degree in epidemiology from Harvard School of Public Health, where he is currently an Adjunct Professor of Epidemiology. Dr. Fraumeni has spent his entire research career at the National Cancer Institute, where he has developed and directed the epidemiology and biostatistics program. For his outstanding achievements in elucidating the environmental and genetic determinants of cancer, Dr. Fraumeni received the American Cancer Society Award for Research Excellence in Epidemiology and Prevention in 1993. An AACR member since 1968, Dr. Fraumeni was on the Board of Directors from 1983 to 1986. In recent years, he served on the Long-Range Planning Committee from 1990 to 1993 and the Nominating and Publications Committees from 1993 to 1995. He also chaired the American Cancer Society Subcommittee of the Awards Committee from 1993 to 1994. Dr. Fraumeni has been an Associate Editor for Cancer Research since 1974. He has also served as an Associate Editor for Cancer Epidemiology, Biomarkers & Prevention since its inception in November 1991.

Dr. Harlow made a discovery which led to a growing understanding of the crucial role tumor suppressor genes play in human cancer, particularly how the blocking of the Rb gene can lead to the uncontrolled cell growth that is the hallmark of cancer. Dr. Harlow received his B.S. and M.S. from the University of Oklahoma and his Ph.D. at the Imperial Cancer Research Fund in London. He joined the Cold Spring Harbor Laboratory in 1982 and moved to Massachusetts General Hospital Cancer Center in 1990. Dr. Harlow has served the AACR in various capacities, including as a member of the Program Committee for the conference “Normal and Neoplastic Growth and Development” (October 1992, Chatham, MA) and as Co-Chair of the “Awards Conference: Cancer and the Cell Cycle,” to be held in January 1996 in Lausanne, Switzerland.

We are indebted to the General Motors Cancer Research Foundation and those featured for the information and photographs used for this cover feature.

Sidney Weinhouse